




STATE MEDICAID P&T COMMITTEE MEETING
THURSDAY, April 18, 2013
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 128



MINUTES

Committee Members Present:

Ellie Brownstein, M.D.
 Lisa Hunt, R.Ph.
 Bernadette Kiraly, M.D.
 Julia Ozbolt, M.D.

Kort Delost, R.Ph.
 Beth Johnson, R.Ph.
 Roger Martenau, M.D.

Committee Members Excused:

Jameson Rice, Pharm.D.

Elizabeth Young, Pharm.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, Pharm.D.
 Richard Sorenson, R.N.
 Trevor Smith, CPhT

Bobbi Hansen, CPhT.
 Tim Morley, R.Ph.

University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Other Individuals Present:

Paul Bonham, NovoNordisk
 Alan Bailey, Pfizer
 Gary Oderda, UofU
 Molly Meekin

Wayne Roberts, GSK
 Scott Larson, BMS
 Efrain Alton, Merck

Meeting conducted by: Ellie Brownstein

- 1 Review and Approval of March Minutes: Kort Delost made a motion to approve the minutes. Julia Ozbolt seconded the motion. The motion was approved unanimously.
- 2 Housekeeping: Lisa Hunt reported that a new/updated PDL was posted to the Medicaid Pharmacy website April 16, 2013. She also reviewed the tentative P&T Committee meeting schedule for the remainder of 2013. Lisa Hunt reminded Committee members and guest to sign-in on the meeting rosters.
- 3 Drug Utilization Review (DUR) Board update: Robyn Seely reported that in April 2013 the DUR board reviewed urinary antispasmodics, the board determined that agents used to treat overactive bladder should remain available without a prior authorization. In May the DUR Board will be reviewing Merbetriq (due to its different mechanism of action, it was not reviewed in April 2013).

- 4 Nomination of P&T Committee Chairperson: Lisa Hunt reported that once each year the Committee is required to elect a Committee chairperson. She asked for Committee recommendations. She explained that in the past the Committee has generally rotated between physicians and pharmacists in the position of Committee chairperson. Ellie Brownstein added that at times they have had dual chair-people (filling both those areas of credentials). Lisa Hunt asked if Kort Delost was interested in being the P&T Committee chairperson.

Roger Martineau made a motion to accept Kort Delost as the next P&T Committee chairperson. Julie Ozbolt seconded the motion. The motion was approved unanimously. Kort will take over the position at the following month's meeting.

- 5 P&T Committee Training Material (Review and Approval): Lisa Hunt presented a draft training manual to be used for new members to the Committee for feedback and/or approval. She explained that the P&T Committee is a sub-committee of the DUR Board. The goal of the P&T Committee is to establish the Preferred Drug List and to provide direction and recommendations to the Division (of Medicaid and Health Financing). The Committee is to make recommendations based off safety and efficacy within each therapeutic class.

Lisa Hunt provided an overview of the required credentials that the Committee is required to seat. She added that each member is required to sign a Conflict of Interest Disclosure form, stating no direct compensation is being received from the pharmaceutical industry. She asked each of the Committee members to fill-out an updated Conflict of Interest Disclosure form to keep on record.

Lisa Hunt reported that the Attorney General's office came down with a determination that the P&T Committee could not discuss costs. Federal law around rebates makes the specific amounts confidential. With the recommendations from the Committee State staff must then review cost to make a final determination whether the product will be preferred or non-preferred.

Lisa Hunt went over the contracts that are held in relation to the P&T Committee. The University of Utah holds the current contract to provide expertise and clinic study data. There is also a membership with the Sovereign States Drug Consortium (SSDC), which holds memberships with eight different state Medicaid programs. The SSDC works with drug manufacturers to negotiate rebates. Goold Health Systems (GHS) is the engine that collects and reports the bids to the State for consideration. Each state within the SSDC can choose what to prefer and non-prefer.

Attachments to training manual include the code that establishes the Preferred Drug List (PDL), the administrative rule behind the PDL program, a copy of the disclosure statement, and bylaws which the Committee has the option to adopt. After a brief review Kort Delost made a motion to accept the bylaws. Beth Johnson seconded the motion. The motion was approved unanimously.

Bernadette Kiraly made a motion to add (informal) Robert's Rules of Order to the training manual and with that addition approve the manual for use. Ellie Brownstein

seconded the motion. The motion was approved unanimously.

Lisa Hunt asked each of the Committee members to update their contact information so she has a way to keep them updated of upcoming meetings and meeting changes. She also asked the Committee members to update their disclosure forms.

- 6 Open Public Meeting Act Training: Milda Shibonis, J.D. provided Open Public Meetings Act training to the committee. Handouts were provided to committee members (in meeting packets) highlighting applicable points and rules to follow from the Act.

Lisa Hunt made a motion to add the Open Public Meetings Act training handout to the P&T Committee training manual. Ellie Brownstein seconded the motion. The motion was approved unanimously.

Next Meeting Set for Thursday, May 16, 2013 – Sulfonylurea Drug Class review
Meeting Adjourned.
Minutes prepared by Bobbi Hansen.